Curiox Biosystems Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on Curiox Biosystems's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Life Sciences Industry Growth | 53.7% |
| Revenue growth rate | n/a |
| Return on equity | -19.0% |
| Net Margin | -147.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Revenue & Expenses BreakdownBeta
How Curiox Biosystems makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 6,788 | -10,040 | 10,592 | 2,109 |
| 30 Sep 23 | 7,113 | -11,594 | 11,169 | 2,460 |
Quality Earnings: A445680 is currently unprofitable.
Growing Profit Margin: A445680 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if A445680's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare A445680's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A445680 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (7.5%).
Return on Equity
High ROE: A445680 has a negative Return on Equity (-18.99%), as it is currently unprofitable.